Risk factor
Resilient to price shocks
Profitability factor
Greatly overvalued vs peers
About
Financière de Tubize SA, through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, overvalued on P/FC.
Target Price
The average target price of TUB.BR is 240 and suggests 9% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell